Moreover, two important lines of research must be developed: (1) the use of GAL analogs in tumors expressing certain GALRs; and (2) targeted radionuclide cancer therapy: the use of GAL and non-peptide ligands as radiopharmaceuticals for the diagnosis/treatment of GALR-positive tumors. This evidence concerns the gene GAL and cancer.